CD24Fc ameliorates immune-related adverse events while preserving anti-tumor therapeutic effect

• Mingyue Liu,
• Xu Wang,
• Xuexiang Du,
• Yan Zhang,
• Chunxia Ai,
• Siwen Hu-Lieskovan,
• Tianhong Li,
• Martin Devenport,
• Yang Liu,
• Pan Zheng

Affiliations

Mingyue Liu

Division of Immunotherapy, Institute of Human Virology and Department of Surgery, University of Maryland School of Medicine

Xu Wang

Division of Immunotherapy, Institute of Human Virology and Department of Surgery, University of Maryland School of Medicine

Xuexiang Du

Division of Immunotherapy, Institute of Human Virology and Department of Surgery, University of Maryland School of Medicine

Yan Zhang

Division of Immunotherapy, Institute of Human Virology and Department of Surgery, University of Maryland School of Medicine

Chunxia Ai

Division of Immunotherapy, Institute of Human Virology and Department of Surgery, University of Maryland School of Medicine

Siwen Hu-Lieskovan

Division of Oncology, Huntsman Cancer Institute, University of Utah School of Medicine

Tianhong Li

Division of Hematology/Oncology, Department of Internal Medicine, University of California Davis School of Medicine, University of California Davis Comprehensive Cancer Center

Martin Devenport

OncoC4, Inc

Yang Liu

Division of Immunotherapy, Institute of Human Virology and Department of Surgery, University of Maryland School of Medicine

Pan Zheng

Division of Immunotherapy, Institute of Human Virology and Department of Surgery, University of Maryland School of Medicine